T
Tempest Therapeutics, Inc. (TPST)
NCM – Real vaqt narxi. Valyuta: USD
1.08
+0.03 (2.86%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
1.08
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 7:08 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
1.08
+0.03 (2.86%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
1.08
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 7:08 PM EDT
Tempest Therapeutics, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, saratonni davolash uchun kichik molekulali terapevtik vositalarni ishlab chiqadi. Uning asosiy mahsulot nomzodlari orasida Amezalpat, peroksizom proliferator bilan faollashadigan alfa retseptorining og'iz orqali qabul qilinadigan kichik molekulali selektiv antagonist, birinchi liniyali rezektsiya qilinmaydigan yoki metastatik gepatotsellyulyar karsinomani davolash uchun, 2-bosqichli klinik sinovni yakunlagan; va TPST-1495, prostaglandin E2 ning EP2 va EP4 retseptorlarining kichik molekulali er-xotin antagonist, turli saraton turlarini davolash uchun. Kompaniya Amezalpatni global birinchi liniyali randomizatsiyalangan tadqiqotga aylantirish uchun F. Hoffmann-La Roche Ltd. bilan hamkorlik shartnomasiga ega. Tempest Therapeutics, Inc. shtab-kvartirasi Brisben, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Andrew Fang Ph.D. | Head of Business Development |
| Mr. Justin Trojanowski CPA | Corporate Controller, Treasurer & Principal Accounting Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-23 | D | |
| 2026-06-23 | 8-K | d158247d8k.htm |
| 2026-06-08 | DEF 14A | ny20072803x2_def14a.htm |
| 2026-06-04 | 8-K | d91703d8k.htm |
| 2026-06-02 | 8-K | d105562d8k.htm |
| 2026-05-29 | PRE 14A | ny20072803x1_pre14a.htm |
| 2026-05-29 | 8-K | d220128d8k.htm |
| 2026-05-22 | 8-K | d29824d8k.htm |
| 2026-05-14 | 8-K | tpst-20260514.htm |
| 2026-05-14 | 10-Q | tpst-20260331.htm |